GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Santhera Pharmaceuticals Holding SANN.SW · CHF

Health Care · SIX · 🇨🇭 Switzerland

Compare

15.20

+1.88%

Close of 9 Nov 2026, in CHF

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

7 analysts, 1 Feb 2026. The analysts' own views, not ours.

  • 2Strong buy
  • 4Buy
  • 1Hold
  • 0Sell
  • 0Strong sell

Price targets

Brokers' own targets, 1 Feb 2026. Not our view.

Average target 30.60

Low
30.30
Average
30.60
Median
30.60
High
31.50

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
RevenueCHF 85.2mCHF 106.5mCHF 137.1mCHF 189.1mCHF 196.3m
Revenue, highestCHF 93.8mCHF 117.1mCHF 147.6mCHF 203.6mCHF 211.4m
Revenue, lowestCHF 76.6mCHF 96.0mCHF 126.6mCHF 174.6mCHF 181.2m
Earnings per share-3.17-0.190.783.244.60
Earnings per share, highest0.180.250.853.575.06
Earnings per share, lowest-6.51-0.630.702.924.14
Analysts22111

Earnings against forecasts

Earnings per share by fiscal quarter

Q3 2026Q1 2026Q3 2025Q1 2025Q2 2024
Forecast-0.09-0.09-0.60-0.74-0.94
Reported-1.50-0.79-3.04-2.09-1.35
Difference-1566.7%-777.8%-406.7%-182.4%-43.6%

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

5 / 10

Revenue growth 33.4% a year over 10 years. Return on equity 416.7%.

Model fair value

9.71

From earnings 9.71, from revenue 16.96.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.